Preclinical screening for drug-induced mitochondrial dysfunction can predict toxicity and revolutionizedrug development

All too often, despite adherence to regulatory guidelines, a new drug reaches the market and its toxicity is not discovered until many patients have been exposed. In many cases, this unpredicted toxicity is due to the drug's adverse effects on mitochondrial function or replication. This reference presents technological developments that facilitate preclinical drug evaluation for potential mitochondrial toxicity, addressing the issue early in the drug development process. With chapters contributed by leading specialists in their areas, Drug-Induced Mitochondrial Dysfunction:

Explains basic concepts so that non-specialists can understand mitochondrial function

Discusses mitochondrial etiology of organ toxicity, covering the liver, heart, and kidney, as well as the skeletal muscle, nervous system, and lipoatrophy

Details methodologies and techniques used to assess mitochondria function so researchers can address drug-induced mitochondrial impairment in their own labs

Includes new models that detect drug-induced mitochondrial impairment in short-duration studies typical of preclinical drug evaluations

Features both in vitro and in vivo methods for analysis, including practical screening approaches for drug discovery and development

This is the authoritative reference on drug-induced mitochondrial dysfunction for safety assessment professionals in the pharmaceutical industry, including bench scientists and managers, and for pharmacologists and toxicologists in both drug and environmental health sciences.